Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Säkerhet och prestanda för LINEA hjärtstimuleringsledning optimerad för implantation i septum mellan hjärtkammarna (STARLIGHT)

18 september 2026 uppdaterad av: MicroPort CRM

Säkerhet och prestanda för LINEA-kardiostimuleringsleden optimerad för implantation i interventrikulär septum

The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

450

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria (phase I and II):

  • Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
  • Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
  • Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
  • Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated

Exclusion criteria (phase I and II):

  • Patient planned for a device upgrade, or a device or a lead replacement
  • Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
  • Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
  • Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
  • Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
  • Patient with a life expectancy of less than 2 years
  • Minor age patient (i.e. under 18 years of age)
  • Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
  • Non-menopausal women

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: LINEA kardiostimulationsledare

Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
LINEA lead complication free rate at 3 months
Tidsram: 3 months after implantation

Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death

3 months after implantation
LINEA lead pacing threshold amplitude at 3 months
Tidsram: 3 months after implantation

Mean ventricular pacing threshold amplitude

3 months after implantation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Success rate of LINEA lead minimum sensed amplitude
Tidsram: 3 months after implantation

Proportion of patients with minimum sensed amplitude ≥ 5 mV

3 months after implantation
General performances of LINEA lead
Tidsram: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation

Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement

Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
Safety of the LINEA lead
Tidsram: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation

LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead

Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Tidsram: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation

FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter

Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
LINEA lead implantation success rates
Tidsram: Implantation

Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria

Implantation
Lead and delivery catheter implantation time
Tidsram: Implantation

Total procedural time and total fluoroscopic time of each implantation

Implantation
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Tidsram: Implantation

Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good)

Implantation
Right Ventricular Autothreshold performances
Tidsram: 3 months after implantation

- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit

3 months after implantation
Evolution of LBBAP capture over time
Tidsram: 18 months after implantation

- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected

18 months after implantation

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Tidsram: 1 month after implantation

Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting

1 month after implantation
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Tidsram: 1 month after implantation

Mean ventricular pacing threshold amplitude

1 month after implantation
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsram: 1 month after implantation

- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision

1 month after implantation
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsram: 1 month after implantation

- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude)

1 month after implantation
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsram: 1 month after implantation

- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death

1 month after implantation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 juni 2026

Primärt slutförande (Beräknad)

31 januari 2027

Avslutad studie (Beräknad)

30 april 2030

Studieregistreringsdatum

Först inskickad

26 november 2025

Först inskickad som uppfyllde QC-kriterierna

5 januari 2026

Första postat (Faktisk)

15 januari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • LLAI01 - STARLIGHT

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera